Paid Lung Cancer Clinical Trials
Lung cancer clinical trials now enrolling. Access immunotherapy and targeted treatments. Compensation available for qualifying participants with NSCLC or SCLC.
Compensation
$1,500 - $4,500
Duration
24-104 weeks
Phase
Phase I/II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 18 years or older
- Histologically or cytologically confirmed lung cancer (NSCLC or SCLC)
- Known tumor mutation status (EGFR, ALK, ROS1, KRAS, etc.)
- Measurable disease per RECIST criteria
- ECOG performance status 0-2
- Life expectancy of at least 3 months
Who May Not Qualify
- Symptomatic brain metastases
- Prior severe reaction to immunotherapy
- Active interstitial lung disease
- Uncontrolled pleural effusion
- Recent major surgery within 4 weeks
Frequently Asked Questions
What lung cancer treatments are currently being studied?
+
Trials are investigating checkpoint inhibitors, targeted therapies for specific mutations (EGFR, ALK, KRAS G12C), antibody-drug conjugates, and novel combination approaches. Both first-line and later-line treatments are being studied.
Do I need to know my tumor mutation status?
+
Yes, most studies require molecular testing results. If you have not had this testing, it may be performed as part of the screening process at no cost to you.
Can I participate with stage IV lung cancer?
+
Yes, many trials specifically enroll patients with advanced or metastatic lung cancer. These studies often provide access to promising new therapies.
What happens if my cancer progresses during the study?
+
If your cancer progresses, the study team will discuss options with you, which may include transitioning to another study arm, accessing other treatments, or returning to standard care.